International Psoriasis Council

Advancing Knowledge. Improving Care.

alvaro gonzalez cantero headshot

Álvaro

González-Cantero

,

MD, PhD

Consultant Dermatologist, Associate Professor
Hospital Ramón y Cajal University Hospital
Madrid
,
Spain
2021 Fellow
Councilor Since: January 1, 2023
IPC Councilor
Dr. Alvaro González-Cantero, MD, PhD, works as a dermatologist at the Department of Dermatology of the Ramón y Cajal University Hospital in Madrid, Spain, where he combines patient care with research. He received his PhD in psoriasis and comorbidities in 2019. He is the principal investigator for a cohort study investigating the pathophysiological mechanisms underlying cardiovascular comorbidity in psoriasis. Dr. González-Cantero has received independent and competitive research funding as principal investigator from the National Psoriasis Foundation (NPF) and the Spanish government. He has published extensively on the link between inflammation, atherosclerosis, and metabolic diseases in prestigious journals such as the Journal of Investigative Dermatology, Lancet, and the European Journal of Preventive Cardiology, among others. He has lectured on psoriasis at international meetings (AAD, EADV, SID). Dr. Gonzalez-Cantero has received numerous local and national awards and honors, including being named the best specialist in Spain. He is actively involved in several foundations and organizations in membership and leadership capacities, including the International Psoriasis Council (IPC), the Psoriasis Task Force of the EADV, and the National Psoriasis Foundation. He also serves as a reviewer for several international grant organizations and biomedical journals.
Last Updated:
11/04/2022

Areas of Interest

Psoriasis and comorbidities; the impact of psoriasis treatments on comorbidities; early intervention in psoriasis; psoriasis and lifestyle; mechanistic studies in psoriasis.

IPC Committees / Groups

Disease Severity Working Group

Languages Spoken

English, Spanish

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026